Aim: To investigate the safety and efficacy of β ray brachytherapy in treatment of vasoproliferative tumours of the retina (VTR). Methods: 35 consecutive patients with symptomatic VTR were treated ...

Golden episcleral plaque with radioactive seeds Eye brachytherapy surgical placement for targeted radiation. Female medical professional surgeon focus on a critical procedure, demonstrating precision ...

Proportion of patients with best corrected visual acuity 15-letter loss from time of randomization and time of completion of plaque brachytherapy (PB) as the primary endpoint for PB patients.

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type D meeting on the ...

Additional secondary end points include overall response rate, defined as >20% ocular tumor shrinkage by product of diameters, proportion of patients with clinically significant macular edema, ...

Plaque brachytherapy: radiation therapy used to treat eye tumors. Progression-free survival: the length of time during and after treatment that a patient lives with the disease but it does not get ...

Background To report on local tumour control, eye preservation and visual outcome after ruthenium-106 brachytherapy for uveal melanoma. Methods Medical records of 143 eyes with uveal melanoma, treated ...

The following is a summary of “Adjuvant Brachytherapy Using Iodine-125 Plaques for Conjunctival Melanoma with Scleral Invasion,” published in the March 2025 issue of Seminars in Ophthalmology by ...

Internal radiotherapy is also called brachytherapy. It can treat some types of eye cancer by using a small radioactive disc called a plaque. This is called plaque radiotherapy. When you might have it.

Incorporating guidance from the FDA meeting, IDEAYA said it projects the enrolment of approximately 400 patients in the randomised Phase III trial, with darovasertib in the treatment or control arm.

For the plaque brachytherapy cohort, the randomization will be darovasertib followed by plaque brachytherapy versus plaque brachytherapy alone. Key highlights of the target registrational trial design ...

Among 31 enucleation and 18 plaque brachytherapy premetastatic uveal melanoma patients who received neoadjuvant darovasertib, 24 (49%) achieved at least 30% ocular tumor shrinkage.